



[Home](#) / [Investors](#) / [News Releases](#)

Insmmed to Host Third Quarter 2016 Financial Results Conference Call on Thursday, November 3, 2016

BRIDGEWATER, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its third quarter financial results on Thursday, November 3, 2016.

Will Lewis, president and chief executive officer, and Andy Drechsler, chief financial officer, will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, November 3, 2016 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (877) 698-3991 (domestic) or (817) 522-1636 (international) and referencing conference ID number 4675771. The call will also be webcast live on the internet on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through November 17, 2016 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 4675771. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmmed's earlier-stage clinical pipeline includes INS1007, a novel oral inhibitor of dipeptidyl peptidase I with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, a nebulized prodrug formulation of treprostinil that may offer a differentiated product profile for rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma. To complement its internal research, Insmmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit www.insmed.com.

"Insmmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
